8-K: 4D Molecular Therapeutics Stockholders Elect Directors, Ratify Auditor, and Approve Executive Compensation at Annual Meeting

4D Molecular Therapeutics, Inc. announced the successful outcomes of its 2025 Annual Meeting of Stockholders, with all four proposals, including director elections and auditor ratification, receiving majority approval.

Summary

• 4D Molecular Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders virtually via the internet on June 17, 2025.
• As of the record date, April 21, 2025, there were 46,324,642 shares of common stock outstanding, each entitled to one vote.
• A total of 38,470,536 shares were voted in person or by proxy at the Annual Meeting.
• Stockholders elected three Class II director nominees to the Board of Directors to serve until the 2028 Annual Meeting: Jacob Chacko, M.D., MBA (28,579,453 votes For), Susannah Gray, MBA (31,923,027 votes For), and Charles P. Theuer, M.D., Ph.D. (27,285,806 votes For).
• The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 38,380,552 votes For.
• Stockholders approved, on an advisory, non-binding basis, the named executive officers' compensation with 31,841,967 votes For.
• Stockholders approved, on an advisory, non-binding basis, a one-year frequency for future advisory votes on named executive officer compensation, with 32,152,558 votes for the 1-year option.
• The Company's Board of Directors determined that future advisory votes on executive compensation will be held annually until the next frequency vote.

Sentiment

Score: 7

Explanation: The sentiment is positive as all proposals passed with strong shareholder support, indicating stable corporate governance and alignment between management and stockholders. There are no negative or unexpected outcomes reported.

Positives

• All four proposals presented at the Annual Meeting received majority stockholder approval, indicating strong alignment between management and shareholders.
• The election of all nominated Class II directors ensures continuity and stability in the Board of Directors.
• The ratification of PricewaterhouseCoopers LLP as the independent auditor provides assurance regarding the company's financial oversight.
• The advisory approval of named executive officer compensation suggests shareholder confidence in the company's compensation practices.
• The decision to hold annual advisory votes on executive compensation aligns with best practices in corporate governance and shareholder engagement.

Future Outlook

The company has determined that it will hold future advisory votes on the compensation of its named executive officers on an annual basis until the next stockholder advisory vote on the frequency of such votes.

Management Comments

• The Company's Board of Directors recommended the one-year frequency for future advisory votes on named executive officer compensation, which was subsequently approved by stockholders.

Industry Context

This 8-K filing details routine corporate governance matters typical for publicly traded companies, particularly in the biotechnology sector, ensuring compliance with SEC regulations and shareholder engagement regarding board composition, auditor oversight, and executive compensation practices.

Comparison to Industry Standards

• The election of directors by majority vote is a common practice in corporate governance, aligning with standards for public companies.
• The ratification of an independent registered public accounting firm is a standard annual procedure for publicly traded companies to ensure financial transparency and accountability.
• Holding advisory, non-binding votes on executive compensation and the frequency of such votes (Say-on-Pay and Say-on-Frequency) are standard practices mandated by the Dodd-Frank Wall Street Reform and Consumer Protection Act for U.S. public companies, reflecting a commitment to shareholder input on compensation matters.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The successful passage of all proposals, including director elections and executive compensation approval, indicates strong shareholder support and alignment with the company's current governance and management. The annual frequency for executive compensation votes provides regular opportunities for shareholder input.
• Management: The approval of executive compensation and the election of nominated directors reflect confidence in the current leadership and their strategic direction.
• Employees: While not directly addressed, stable governance and positive shareholder relations can contribute to a more stable and confident work environment.

Next Steps

• The elected Class II directors will hold office until the 2028 Annual Meeting of Stockholders.
• PricewaterhouseCoopers LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• Future advisory votes on named executive officer compensation will be held on an annual basis until the next stockholder advisory vote on frequency.

Key Dates

Keywords

4D Molecular Therapeutics, FDMT, Annual Meeting, Stockholders, Proxy Statement, Director Election, Auditor Ratification, Executive Compensation, Corporate Governance, SEC Filing, 8-K, Biotechnology, Gene Therapy